but one of the conclusions of the pilot was that a pre-requisite for adoption will be "robust systems in place ensuring that the patient can easily access the package leaflet for their medicine in ...
Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback